Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × HR+/HER2- Breast Cancer × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 119 Breast Neoplasms 78 Neoplasms 71 Colorectal Neoplasms 66 Prostatic Neoplasms 56 Ovarian Neoplasms 51 Melanoma 48 Neoplasm Metastasis 47 Lung Neoplasms 44 Pancreatic Neoplasms 43 Multiple Myeloma 43 Recurrence 42 Leukemia, Myeloid, Acute 38 Lymphoma 37 Stomach Neoplasms 36 Triple Negative Breast Neoplasms 33 Squamous Cell Carcinoma of Head and Neck 31 Lymphoma, Non-Hodgkin 30 Glioblastoma 30 Lymphoma, Large B-Cell, Diffuse 29 Endometrial Neoplasms 27 Carcinoma, Renal Cell 27 Sarcoma 26 Leukemia, Lymphocytic, Chronic, B-Cell 26 Small Cell Lung Carcinoma 25 Precursor Cell Lymphoblastic Leukemia-Lymphoma 25 Myelodysplastic Syndromes 24 Uterine Cervical Neoplasms 22 Lymphoma, Follicular 22 Advanced Solid Tumors 21

Interventions

Letrozole 1 Fulvestrant 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06998407 2026-02-20

AVZO-023-1001

Avenzo Therapeutics, Inc.

Phase 1/2 Recruiting

HR+/HER2- Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡